An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future

Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used

(2010) J. G. Pasipanodya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

(2010) T. Gumbo   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pulmonary impairment after tuberculosis and its contribution to TB burden

(2010) Jotam G Pasipanodya et al.   BMC PUBLIC HEALTH

Efflux‐Pump–Derived Multiple Drug Resistance to Ethambutol Monotherapy inMycobacterium tuberculosisand the Pharmacokinetics and Pharmacodynamics of Ethambutol

(2010) Shashikant Srivastava et al.   JOURNAL OF INFECTIOUS DISEASES

Meningeal Tuberculosis

(2010) Joanna E. T. Shaw et al.   MEDICINE

Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy

(2010) Salim S. Abdool Karim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fluoroquinolone Resistance inMycobacterium tuberculosis

(2009) Rose A. Devasia et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs

(2009) S. Goutelle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bacterial Strain-to-Strain Variation in Pharmacodynamic Index Magnitude, a Hitherto Unconsidered Factor in Establishing Antibiotic Clinical Breakpoints

(2009) A. P. MacGowan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

(2009) T. Gumbo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: Concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum

(2009) S Prakash et al.   Journal of Postgraduate Medicine

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

(2009) Marcus B Conde et al.   LANCET

Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rifapentine

(2008)   TUBERCULOSIS